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Letters to the EditorHowever, the real question that our spe-
cialty needs to address is this: How
should cardiac surgery deal with the
fact that technology changes rapidly,
that the potential therapeutic options
for patients increase faster thanprospec-
tive trials can evaluate them, and that
each year patients who undergo cardiac
surgery continue to be sicker, older, and
at higher risk for complications?
Currently, significant and often un-
perceived conflicts of interest exist
for everyone involved, and it is diffi-
cult for the patient to make a well-
informed opinion. As patients get
sicker and hear about advancing tech-
nology, they are more likely to have
unrealistic expectations. New technol-
ogy is often offered to patients more as
part of amarketing tool than as a proven
therapy.Often, both the surgeon and the
cardiologist will be reimbursed from
a newer hybrid technique. Conflict of
interest can arise from the need tomain-
tain referral patterns and maintain reim-
bursement. The patient is unlikely to
argue against a smaller incision involv-
ing a newer approach, even if the newer
approach has not been proven to be as
good as the current standard of care.
Dr Alec Patterson, President of the
American Association of Thoracic
Surgery, highlights in his presidential
address a need for a change in our pro-
fessional behavior from the individual
to the team approach to care. This
change is likely to be a solution to these
potential conflicts. Patients with cardio-
vascular disease should be offered the
benefits of a multidisciplinary team ap-
proach. This approach has existed for
many years (eg, tumor boards and
transplant selection conferences) but
is not routinely practiced in cardiovas-
cular surgery. A multidisciplinary ap-
proach requires that a regular meeting
take place at which all of the consul-
tants are present to review the data, dis-
cuss what each can offer, and propose
a therapeutic plan. Such an approach
lays the groundwork for the patient to
benefit from the expertise of the entire
team and the foundation from which
all new technologies and therapies can724 The Journal of Thoracic and Cbe evaluated as they continuously sur-
face. The multidisciplinary approach
is to medicine what the scientific
method is to research: the best defense
against conflict of interest.1 Thus this
approach will always keep the patient’s
best interest at the center of our focus.
Octavio E. Pajaro, MD, PhD
University of Alabama at Birmingham
Birmingham, AlaReference






We read with great interest the con-
tribution by ElBardissi and associates1
addressing a controversial issue: the
need for early antithrombotic therapy
in patients with tissue valves. The au-
thors sought to determine whether
this therapy was necessary in patients
in sinus rhythm with a tissue valve in
the aortic position. Their sample of
861 patients is large enough to con-
clude that early anticoagulation after
isolated aortic valve replacement with
a tissue valve does not reduce the
risk of thromboembolism.
The authors are right as to whether
anticoagulation is a must or not in this
type of patients and refer to the recent
American Heart Association/American
College of Cardiology and European
Society of Cardiology recommenda-
tions. The impactful and classic paper
byHeras and colleagues,2 summarizing
an experience from the Mayo Clinic,
led to the consideration of anticoagula-
tion as an adjunct of choice based on
a retrospective analysis during a long
period of time with special focus on pa-
tients with no antithrombotic therapy.
The results of the study of ElBardissi
and associates1 give additional light to
previous publications confirming thatardiovascular Surgery c September 201the 90-day risk of thromboembolism
was 5% in both groups with or without
anticoagulation. The authors identified
classic risk factors for thromboembolic
complications, such as advanced age,
female gender, short stature, smoking,
and a 19-mm valve. We fully agree
with this and their final conclusion.
The authors refer to thromboembo-
lism and the lack of randomized studies
to confirm their conclusion. That was
our concern when we designed our pro-
spective and randomized pilot trial.3 In
this cooperative pilot study, 193 pa-
tients were randomized to acenocu-
marol and triflusal (an antiplatelet
agent) for primary prevention of throm-
boembolism early after tissue valve im-
plantation; 93.8% were aortic valves.
We3 aimed at evaluating the efficacy
and safety of antiplatelet therapy versus
acenocumarol with the primary end
point of a composite of thromboembo-
lism, hemorrhage, and valve-related
mortality. The results of our random-
ized trial were that the rate of thrombo-
embolic events was not significantly
different among groups, thereby con-
firming that antiplatelet therapy was
an equally protective strategy. In addi-
tion, there was a statistically significant
difference favoring the antiplatelet
group in terms of hemorrhagic events.
The conclusions of this first reported
randomized trial comparing antiplatelet
versus anticoagulant therapies were
that there was a safer profilewith signif-
icantly lower bleeding in the antiplate-
let group. The results by ElBardissi
and coworkers1 are consistent with
these data in terms of protection against
thromboembolic events. Despite some
limitations in our design that have
already been addressed, we strongly
believe that early anticoagulationmight
not be the ideal therapy considering the
currently accumulated experience that,
of course, includes this very appropri-
ate and updated experience by ElBar-
dissi and colleagues.1
Finally, similar conclusions were
recently reached by Brueck and
associates.4 They also addressed
patients with no risk factors for0
Letters to the Editorthromboembolism. We5 also sup-
ported this strategy. ElBardissi and
colleagues1 are to be congratulated
for their elegant, albeit retrospective
institutional analysis that brings
additional light to this controversial
problem. Once again, there is a
need to revise current guidelines
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doi:10.1016/j.jtcvs.2010.04.032Reply to the Editor:
We appreciate the comments from
Drs Mestres and Aramendi regarding
our retrospective institutional analysis,The Journalwhich identified no difference in the
overall incidence of thromboembolic
events in patients who electively re-
ceived anticoagulants after bioprosthetic
aortic valve implantation.1 Althoughwe
identified subsets of patients that may
benefit from some form of antithrom-
botic therapy in the immediate postoper-
ative phase (either antiplatelet therapy or
a vitamin K antagonist with a goal inter-
national normalized ratio of 2 to 3), our
findings differ markedly from the
American Heart Association/American
College of Cardiology (AHA/ACC)
andother international cardiac organiza-
tions, which recommend anticoagula-
tion with a vitamin K antagonist for
the first 90 postoperative days.2
Since publication of the article by
Heras and associates3 from the Mayo
Clinic that ultimately inspired these
aggressive anticoagulation recommen-
dations, there have been a plethora of
retrospective studies suggesting that
anticoagulation is unnecessary and
may be harmful. In fact, Sundt and
colleagues4 recently updated and re-
reviewed the Mayo Clinic series and
found that anticoagulation did not
provide additional protection from
thromboembolic events. Our thorough
analysis of the outcomes from the
Brigham and Women’s Hospital dem-
onstrated that only high-risk groups
may benefit from some type of antith-
rombotic therapy. It should be noted,
however, that in these high-risk pa-
tients, the optimal form of early antith-
rombotic therapy is still up for debate.
In one of the few prospective, ran-
domized, multi-institution studies ex-
amining this important clinical
question, Aramendi and colleagues5
identified an important outcome that
has not been demonstrated in most
single-institution retrospective studies,
including ours: patients who receive
anticoagulation with a vitamin K an-
tagonist have bleeding complications
at a much higher rate than those who
are treated with a platelet inhibitor.
Although these findings may be
intuitive, they warrant recognition inas-
much as surgeons considering antith-of Thoracic and Cardiovascular Surgerombotic therapy in high-risk patients
should be cognizant of the potential
bleeding complications after treatment
with vitamin K antagonists in this spe-
cific group of patients. Further, high-
riskpatients inour analysis had a similar
reduction in thromboembolic events
irrespective of the mode of antithrom-
botic therapy (aspirin versus warfarin
sodium [Coumadin]). These compli-
mentary findings suggest that antiplate-
let therapy after bioprosthetic aortic
valve replacement may provide the
optimal balance between efficacy and
safety.
The time may have come for the
AHA/ACC to reconsider their antith-
rombotic therapy recommendations
after bioprosthetic aortic valve replace-
ment. There now exists a large amount
of data that suggest widespread antico-
agulation is not indicated, and perhaps
more concerning, patients administered
vitamin K antagonists may be at a
significant risk of major bleeding
complications.
Andrew W. ElBardissi, MD, MPH
Lawrence H. Cohn, MD
Division of Cardiac Surgery
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Harvard Medical School
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